CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Bacillus Calmette-Guérin (BCG)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02281383
NCT02281383Phase 2Completed
CompareCT.gov

Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Nov 3, 2014·Updated Feb 8, 2023

In Brief

A Phase 2 clinical trial evaluating Bacillus Calmette-Guérin (BCG) for Bladder Cancer and High Risk Superficial. Completed, enrolled 80 participants across 5 sites.

Detailed Summary

This is a phase II study. This means that BCG therapy has already been found to be safe in humans. The investigators just want to see if using more treatments works better.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer, High Risk Superficial
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 3, 2014
Enrollment StartOct 1, 2014
Primary CompletionFeb 24, 2022
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 11.7 years ago

Interventions

Bacillus Calmette-Guérin (BCG)biological